International Stem Cell Breaks Out Higher
International Stem Cell Corporation [[ISCO.OB]] shares moved up more than 45 percent after it rebounded from a key support level and re-tested its prior highs. The move also comes just one week after the company commented on the National Institute of Health’s proposed research guidelines for stem cells, which could undermine its parthenogenetic stem cell initiatives.
Here is the chart showing ISCO’s retracement before today’s rebound:
International Stem Cell is known for its development of parthenogenetic stem cells, which offer an ethical alternative to traditional stem cell research. The company’s technology allows for the creation of pluripotent human stem cell lines from unfertilized human eggs. These stem cells can be the source of therapeutic cells that will minimize immune rejection after transplantation.
Recently, International Stem Cell was featured in the Data Trends Equity Research Group’s Stem Cell Business news and Stem Cell Research companies report. The independent research provider suggested that the company’s groundbreaking technology may solve critical ethical issues by eliminating the need to use fertilized embryos for research.
CONTACT: 888-288-5215 · Please read our Full Disclaimer pertaining to this article.